Eupraxia Pharmaceuticals (EPRX) Net Income towards Common Stockholders (2023 - 2026)
Eupraxia Pharmaceuticals (EPRX) recorded Net Income towards Common Stockholders of -$14.49 million in the quarter ended Jun 30, 2026, compared with -$8.75 million a year earlier.
Powered by 
Analysis
Eupraxia Pharmaceuticals (EPRX) Net Income towards Common Stockholders (2023 - 2026) Analysis & Trends
On a TTM basis, Eupraxia Pharmaceuticals' Net Income towards Common Stockholders came in at -$50.24 million as of Jun 30, 2026; for the year ended Dec 31, 2025, it was -$38.61 million.
- Across earlier years, Net Income towards Common Stockholders came in at -$25.74 million in the year ended Dec 31, 2024, -$28.97 million in the year ended Dec 31, 2023 and -$18.99 million in the year ended Dec 31, 2022.
- Quarterly Net Income towards Common Stockholders has ranged from -$16.72 million in the quarter ended Dec 31, 2025 to -$3.96 million in the quarter ended Mar 31, 2023 over the past five years.
- Per Business Quant, the preceding three quarters came in at -$12.65 million (quarter ended Mar 31, 2026), -$16.72 million (quarter ended Dec 31, 2025) and -$6.37 million (quarter ended Sep 30, 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 7.10 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 5.53 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 3.61 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | -1.34 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 3.26 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 2.89 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 2.38 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | -10.50 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | -248.00 Mn |
| 10 | Eupraxia Pharmaceuticals | 289.28 Mn | 287.68 Mn | - | -14.49 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -14.49 Mn |
| Mar 31, 2026 | -12.65 Mn |
| Dec 31, 2025 | -16.72 Mn |
| Sep 30, 2025 | -6.37 Mn |
| Jun 30, 2025 | -8.75 Mn |
| Mar 31, 2025 | -6.77 Mn |
| Dec 31, 2024 | -7.53 Mn |
| Sep 30, 2024 | -5.99 Mn |
| Jun 30, 2024 | -6.06 Mn |
| Mar 31, 2024 | -6.16 Mn |
| Dec 31, 2023 | -10.61 Mn |
| Sep 30, 2023 | -4.90 Mn |
| Jun 30, 2023 | -9.51 Mn |
| Mar 31, 2023 | -3.96 Mn |
API Access
Eupraxia Pharmaceuticals Net Income towards Common Stockholders API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=EPRX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "net-income-towards-common-stockholders", "ticker": "EPRX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=EPRX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();